Ahmet Anil Ozluk

Dr. Ahmet Anil Ozluk

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 November 2023 in Current Oncology
Verified
Journal Article
Open access
PDF file
FBFuat Bicer
Fuat Bicer
CKCatrina Kure
Catrina Kure
AOAhmet Anil Ozluk
Ahmet Anil Ozluk
BEBassel F. El-Rayes
Bassel F. El-Rayes
MAMehmet Akce
Mehmet Akce
Hepatocellular carcinoma (HCC) is the second most common cause of cancer-related deaths in the world. More than half of patients with HCC present with advanced stage, and highly active systemic therapies are crucial for improving outcomes. Immune checkpoint inhibitor (ICI)-based therapies have emerged as novel therapy options for advanced HCC. Only one third of patients achieve an objective response with ICI-based therapies due to primary resistance or acquired resistance. The liver tumor microenvironment is naturally immunosuppressive, and specific mutations in cell signaling pathways allow the tumor to evade the immune response. Next, gene sequencing of the tumor tissue or circulating tumor DNA may delineate resistance mechanisms to ICI-based therapy and provide a rationale for novel combination therapies. In this review, we discuss the results of key clinical trials that have led to approval of ICI-based therapy options in advanced HCC and summarize the ongoing clinical trials. We review resistance mechanisms to ICIs and discuss how immunotherapies may be optimized based on the emerging research of tumor biomarkers and genomic alterations.

13 October 2014 in Gastroenterology Research and Practice
Verified
Journal Article
Open access
PDF file
CBCumhur İbrahim Başsorgun
Cumhur İbrahim Başsorgun
BÜBetül Ünal
Betül Ünal
NENuray Erin
Nuray Erin
AOAhmet Anil Ozluk
Ahmet Anil Ozluk
ÖUÖzlem Ceren Uzun
Özlem Ceren Uzun
GEGülsüm Özlem Elpek
Gülsüm Özlem Elpek
Introduction. In colorectal carcinoma, tumoral tissues infiltrate with various immune/inflammatory cells along their invasive margins and the increased S100A8/A9 expression in these immune cells infiltrating the tumor has recently been demonstrated. We examined S100A8/A9 as a potential therapeutic target in the treatment of colorectal carcinoma. Materials and Methods. The current study included a sample of 80 patients diagnosed with CRC (30 cases with distant metastasis, 30 cases with lymph node metastasis, and 20 cases with no metastasis). Peritumoral and intratumoral S100A8 and S100A9 expressing inflammatory cells were counted in primary tumors and their metastasis and correlated with clinicopathological parameters. Results. The peritumoral and intratumoral S100A8/A9 positive cells showed no correlation with age, gender, or depth of tumor invasion. However higher counts of peritumoral and intratumoral S100A8/A9 positive cells were associated with larger tumor size, higher grade, and the presence of metastasis . Conclusion. Our study also found significantly higher number of S100A8/A9 positive cells in the tumor microenvironment among patients with large tumor size, high grade, and metastatic disease. Moreover, in our study, we observed that the expression in the tumor metastasis appeared similar to that of primary tumor.

1 April 2017 in Transplantation Proceedings
Verified
Journal Article
Closed access
MYM. Yilmaz
M. Yilmaz
TST.ö. Sezer
T.ö. Sezer
OKO. Kir
O. Kir
AOAhmet Anil Ozluk
Ahmet Anil Ozluk
CHC. Hoşcoşkun
C. Hoşcoşkun
HTH. Töz
H. Töz

1 December 2016 in Clinical Sarcoma Research
Verified
Journal Article
Open access
PDF file
GBGülcan Bulut
Gülcan Bulut
AOAhmet Anil Ozluk
Ahmet Anil Ozluk
AEATIKE PINAR ERDOGAN
ATIKE PINAR ERDOGAN
RURuchan Uslu
Ruchan Uslu
NENevra Elmas
Nevra Elmas
BKBurçak Şaziye Karaca
Burçak Şaziye Karaca
Aggressive fibromatosis (AF), also known as desmoid tumor, is an uncommon soft tissue neoplasm. AF does not metastasize, but it is locally invasive and its propensity for recurrence after conservative resection is well documented. No effective cytotoxic treatment has been reported, hence there is a need for novel treatment strategies. We present the case of an AF successfully treated with an oral tyrosine kinase inhibitor, pazopanib, with mild side effects. As far as we know, this is the first case of AF with complete response to pazopanib. Pazopanib might be an effective treatment option for AF.

10 August 2024 in Journal of Geriatric Oncology
Verified
Journal Article
Closed access
AOAhmet Anil Ozluk
Ahmet Anil Ozluk
GWGrant Richard Williams
Grant Richard Williams
CDChen Dai
Chen Dai
JGJonathan Goldberg
Jonathan Goldberg
MMMidhun Malla
Midhun Malla
MAMehmet Akce
Mehmet Akce

26 February 2026 in Cancers
Verified
Journal Article
Open access
PDF file
AOAhmet Anil Ozluk
Ahmet Anil Ozluk
WCWilliam Colley
William Colley
ZAZeynep Beyza Arik
Zeynep Beyza Arik
OKOsman Köstek
Osman Köstek
ASAakash Sunkari
Aakash Sunkari
MAMehmet Akce
Mehmet Akce
Circulating tumor DNA (ctDNA) has emerged as a promising and versatile biomarker in colorectal cancer (CRC), providing real-time insights into the tumor burden, minimal residual disease (MRD), and treatment response across both early and metastatic stages. In patients with resected stage II–III CRC, post-operative ctDNA positivity is a robust predictor of recurrence and may outperform traditional clinicopathologic risk factors. It can facilitate adjuvant therapy discussions; however, treatment escalation or de-escalation based solely on ctDNA results is not yet supported by available interventional data. In the metastatic setting, ctDNA-based techniques could provide non-invasive molecular profiling and a monitoring response to systemic therapies. Peripheral blood-based techniques could also help detect emerging resistance to systemic therapy. Emerging evidence highlights that quantitative assessment of ctDNA dynamics, including the baseline burden and post-treatment clearance, could further refine risk stratification and inform treatment personalization. Collectively, ctDNA represents a promising and evolving biomarker with well-established prognostic and emerging predictive potential and is poised to support precision oncology across the continuum of CRC.